01.05.16
MannKind Corp. has terminated its license and collaboration agreement with Sanofi-aventis U.S. for the development and commercialization of Afrezza (insulin human) Inhalation Powder. The companies will transition the development and commercialization of Afrezza from Sanofi to MannKind within 180 days.
MannKind is reviewing its strategic options for Afrezza as a result of the termination of the Sanofi collaboration.
MannKind is reviewing its strategic options for Afrezza as a result of the termination of the Sanofi collaboration.